Brought to you by 
Crescendo Biologics closes $70mm Series B
07 May 2018
Executive Summary
Crescendo Biologics Ltd. (developing T-cell engagers for cancer) raised $70mm through its Series B round. Lead investors Andera Partners (formerly Edmond de Rothschild Investment Partners) and Quan Capital were joined by returning investors Sofinnova Partners, IP Group, EMBL, and Takeda Ventures. Proceeds will help the company advance its lead candidate CB307, a bispecific PSMA-targeted T-cell engager, into clinical trials.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Transgenics
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Crescendo Biologics closes $70mm Series B
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice